Team
Team
Lindsey Arnold
HR and Operations Manager
Dorothy Lou Bailey
President & CEO
READ BIO
Bob Fay
Executive Project Manager
Senior Immunology Advisor
READ BIO
Senior Drug Development Advisor
READ BIO
Senior Medicinal Chemistry Advisor
READ BIO
Sudharsana Ravisankar
Cell/Molecular Biology Co-op, Biology
Ronenn Roubenoff, MD
Senior Clinical Advisor
READ BIO
Alan Saghatelian, PhD
Co-Founder
READ BIO
Academic Founders & Selected Scientific Advisors
David Liu, PhD
Broad, HHMI
Founder: Editas, Beam, Prime, Chroma
David R. Liu, PhD, is the Richard Merkin Professor, Director of the Merkin Institute of Transformative Technologies in Healthcare, and Vice-Chair of the Faculty at the Broad Institute of Harvard and MIT; Thomas Dudley Cabot Professor of the Natural Sciences and Professor of Chemistry and Chemical Biology at Harvard University; and Howard Hughes Medical Institute Investigator.
Dr. Liu has published over 180 papers and is the inventor of over 70 issued U.S. patents. His research accomplishments have earned distinctions including the Ronald Breslow Award for Biomimetic Chemistry, the American Chemical Society Pure Chemistry Award, the Arthur C. Cope Young Scholar Award, and awards from the Sloan Foundation, Beckman Foundation, NSF CAREER Program, and Searle Scholars Program. In 2016 he was named one of the Top 20 Translational Researchers in the world by Nature Biotechnology, and in 2017 was named to the Nature’s 10 researchers in the world and to the Foreign Policy Leading Global Thinkers.
Dr. Liu’s research integrates chemistry and evolution to illuminate biology and enable next-generation therapeutics. His major research interests include the engineering, evolution, and in vivo delivery of genome editing proteins such as base editors and prime editors to study and treat genetic diseases; the evolution of proteins with novel therapeutic potential using phage-assisted continuous evolution (PACE); and the discovery of bioactive synthetic small molecules and synthetic polymers using DNA-templated organic synthesis and DNA-encoded libraries. Base editing (named one of four 2017 Breakthrough of the Year finalists by Science), prime editing, PACE, and DNA-templated synthesis are four examples of technologies pioneered in his laboratory. He is the scientific founder or co-founder of seven biotechnology and therapeutics companies, including Editas Medicine, Pairwise Plants, Exo Therapeutics, Beam Therapeutics, and Prime Medicine.
Dr. Liu graduated first in his class at Harvard in 1994. He performed organic and bioorganic chemistry research on sterol biosynthesis under Professor E. J. Corey’s guidance as an undergraduate. During his PhD research with Professor Peter Schultz at U. C. Berkeley, Liu initiated the first general effort to expand the genetic code in living cells. He earned his PhD in Organic Chemistry from University of California, Berkeley and became Assistant Professor of Chemistry and Chemical Biology at Harvard University in the same year. He was promoted to Associate Professor in 2003 and to Full Professor in 2005. Dr. Liu became a Howard Hughes Medical Institute Investigator in 2005 and joined the JASONs, academic science advisors to the U.S. government, in 2009. Liu has earned several university-wide distinctions for teaching at Harvard, including the Joseph R. Levenson Memorial Teaching Prize, the Roslyn Abramson Award, and a Harvard College Professorship.
Broad, HHMI
Founder: Editas, Beam, Prime, Chroma
Richard Merkin Professor and Director Merkin Institute Core Institute Member Vice-Chair Faculty, Broad Institute Investigator, Howard Hughes Medical Institute
Thomas Dudley Cabot Professor of the Natural Sciences Professor of Chemistry & Chemical Biology, Harvard University
Alan Saghatelian, PhD
Salk Institute
Alan Saghatelian, PhD, is a Professor and Frederik Paulsen Chair at the Salk Institute for Biological Studies and an adjunct Professor at the University of California, San Diego.
Dr. Saghatelian has published over 110 papers and six patents. Saghatelian was a recipient of the NIH New Innovator Award, a Searle Scholar Awardee, and a Sloan Foundation Fellow. Dr. Saghatelian’s research in chemical biology merges modern analytical techniques with biochemistry and chemical biology to identify genes that regulate fundamental biological pathways and can be targeted for the development of novel therapeutics.
Dr. Saghatelian graduated from the University of California, Los Angeles in 1997 with a degree in Chemistry. He carried out organic and organometallic chemistry research on the total synthesis of a marine natural product with anti-cancer activity in the lab of Professor Craig Merlic. He earned his PhD in Chemistry from The Scripps Research Institute in Chemistry working with Professor Reza Ghadiri. During graduate school, Dr. Saghatelian worked to develop new protein and peptide catalysts through chemical synthesis and protein engineering. Dr. Saghatelian performed his postdoctoral research with Professor Benjamin Cravatt at The Scripps Research Institute where he developed novel mass spectrometry approaches for global metabolite profiling. In 2006, Dr. Saghatelian started his independent career as an Assistant Professor in the Department of Chemistry and Chemical Biology at Harvard University, and in 2014, he moved to the Salk Institute for Biological Studies.
Salk Institute
Professor, Salk Institute
Clayton Foundation Laboratories for Peptide Biology
Dr. Frederik Paulsen Chair
Stuart Schreiber, PhD
Broad Institute
Stuart Schreiber, PhD, is co-Founder of the Broad Institute, a Howard Hughes Medical Institute Investigator, and the Morris Loeb Professor of Chemistry and Chemical Biology at Harvard University. His research has been recognized through numerous awards, most recently the Wolf Prize in Chemistry.
Dr. Schreiber’s lab studies the science of therapeutics. Researchers in his group rely on human biology to identify therapeutic targets that have been validated prior to testing in humans, and chemistry and chemical biology to discover small molecules that modulate the targets in ways required to provide relief or protection from disease.
Dr. Schreiber and his group members have discovered principles that underlie information transfer and storage in cells, specifically discoveries relating to signaling by the phosphatase calcineurin and kinase mTOR (demonstrating for the first time that drugs can result from the targeting of protein kinases and protein phosphatases), gene regulation by chromatin-modifying histone deacetylases, small-molecule dimerizers that activate cellular processes by enforced proximity, and small-molecule probes of challenging targets and processes (e.g., transcription factors, oncogenes, protein/protein interactions, transdifferentiation) that relate to human disease. Their work has contributed to diversity-oriented synthesis (DOS) and discovery-based small-molecule screening in an open data-sharing environment.
In current research, the Schreiber lab is studying the mechanisms by which cancers resist therapies by exploring a vulnerability of a cell state that group members discovered as central to resistance of many cancers to many therapies. The lab is also studying a novel mechanism our brains use to maintain brain health, and therapeutic agents that enhance the brain-protective mechanism. Each of these studies is supported by efforts to discover small-molecule “binders” that alter functions of proteins by changing their interactomes and lifetimes. The lab is using modern methods of asymmetric synthesis to yield candidate binders bearing DNA barcodes.
He received his BA in Chemistry from the University of Virginia and his PhD in Organic Chemistry from Harvard University.
Broad Institute
Morris Loeb Professor of Chemistry and Chemical Biology
Howard Hughes Medical Institute Investigator
Benjamin Ebert, MD, PhD
DFCI, HHMI
Benjamin Ebert, MD, PhD, is an institute member of the Broad Institute, the George P. Canellos, MD, and Jean S. Canellos Professor of Medicine at Harvard Medical School, and the chair of medical oncology at the Dana-Farber Cancer Institute. He is also a Howard Hughes Medical Institute investigator.
The Ebert laboratory focuses on the molecular basis and treatment of hematologic malignancies, with a particular focus on myelodysplastic syndromes (MDS). In large-scale genetic analyses of patient samples, the lab has identified somatic mutations that predict prognosis and response to therapies in MDS patients, characterized a pre-malignant state of hematopoietic cells, and derived the molecular ontogeny of genetic lesions in myeloid malignancies. In addition to human genetic studies, the lab has elucidated the biological basis of transformation of hematopoietic cells by these somatic mutations and developed novel in vivo models to study myeloid malignancies. The lab employs genetic and small molecule screens to identify novel therapeutic targets and small molecules for the treatment of hematologic malignancies and sickle cell disease.
In collaboration with the Broad Institute Proteomics Platform, the Ebert lab elucidated the mechanism of action of lenalidomide, a derivative of thalidomide. Lenalidomide and related drugs modulate the function of an E3 ubiquitin ligase, inducing drug-dependent degradation of specific substrates that are essential for the survival of multiple myeloma and MDS cells, representing the first drugs that bind and modulate the function of an E3 ubiquitin ligase.
Dr. Ebert received a bachelor’s degree from Williams College, a doctorate from Oxford University on a Rhodes Scholarship, and an MD from Harvard Medical School. He completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute before pursuing postdoctoral research at the Broad Institute. Dr. Ebert is an elected member of the National Academy of Medicine.
DFCI, HHMI
George P. Canellos, MD, and Jean S. Canellos Professor of Medicine, Harvard Medical School
Chair of Medical Oncology, DFCI
Investigator, HHMI
Institute Member, Broad Institute of Harvard and MIT
Benjamin Cravatt, PhD
Scripps Research Institute
Benjamin F. Cravatt, PhD, is the Gilula Chair of Chemical Biology and Professor in the Department of Chemistry at The Scripps Research Institute. His research group develops and applies chemical proteomic technologies for protein and drug discovery on a global scale and has particular interest in studying biochemical pathways in the nervous system and cancer.
Dr. Cravatt is a co-founder of Activx Biosciences (acquired by Kyorin Pharmaceuticals), Abide Therapeutics (acquired by Lundbeck Pharmaceuticals), and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Royal Society of Chemistry Jeremy Knowles Award, and memberships in the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences. Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a BS in the Biological Sciences and a BA in History. He then received a PhD from The Scripps Research Institute (TSRI) in 1996, and joined the faculty at TSRI in 1997.
Scripps Research Insititute
Gilula Chair of Chemical Biology
Professor, Department of Chemistry
Juan Pablo Maianti, PhD
Harvard Chemistry & Chemical Biology
Dr. Maianti has been a leading author in high-impact research publications across multidisciplinary projects in chemistry, biochemistry, pharmacology, genome editing, and target validation, and is a contributor to over a dozen collaborative manuscripts as well as dozens of patents held by Achaogen Inc., Beam Therapeutics, and Exo Therapeutics. For his research contributions to the understanding of the therapeutic benefits of insulin-degrading enzyme (IDE) inhibitors in type-2 diabetes, the discovery of potent exosite-specific substrate-selective IDE inhibitors, and the development of novel broad-spectrum aminoglycoside antibiotics against ESKAPE pathogens, Dr. Maianti has been awarded The Academic Gold Medal from the Governor General of Canada in 2012, the top recognition for Canadian graduates, The Aldrich Graduate Student Innovation Award in 2013, The Knowles Award 2015 from the Gordon Research Conference, and chosen as a Talented 12 nominee by Chemistry & Engineering News in 2016.
Juan Pablo Maianti earned his PhD from Harvard University in Chemistry and Chemical Biology in 2015 under the supervision of Professor David Liu, following a M.Sc. in Synthetic Organic Chemistry under the supervision of Professor Stephen Hanessian at the University of Montreal in 2011, and B.Sc. in Biochemistry from the University of Canterbury in New Zealand.
Harvard Chemistry & Chemical Biology
Assistant Professor, Albert Einstein College of Medicine, C&EN Talented 12 Award, Canada Academic Gold Medal
Jörg Hans Wilhelm Distler
University Hospital Düsseldorf
Prof. Dr. Jörg Distler is director of the Department of Rheumatology and of the Hiller-Research Center at the University Hospital Düsseldorf of the Heinrich-Heine-University Düsseldorf, Germany. He also holds an affiliation of the Fraunhofer-Institute for Toxicology and Experimental Medicine. He is CEO of 4D Science GmbH and scientific lead and Co-CEO of FibroCure GmbH.
His clinical focus is connective tissue diseases and fibrotic diseases, in particular systemic sclerosis (SSc). His scientific focuses are mesenchymal tissue responses in chronic inflammatory and fibrosing processes.
He and his team are aiming to identify novel targets to interfere with pathological tissue remodeling in fibrotic diseases, to validate them in human and murine models and to translate these findings from bench-to-bedside. Particular areas of interest include target identification by spatial proteomics and transcriptomics, selective targeting of subpopulations of mesenchymal cells in fibrotic diseases, targeting of the epigenetic alterations in fibroblasts (“tissue memory”), molecular imaging of mesenchymal tissue responses and personalized medicine approaches in rheumatic diseases. His work has a strong translational focus: Preclinical work from his group provided the scientific basis for several clinical trials in fibrotic diseases such as SSc. He is principal investigator in numerous international clinical trials (investigator-initiated and industry-sponsored).
He published more than 370 Pubmed-listed articles including over 290 original publications including contributions as senior and corresponding author in journals such as Nature Medicine, Nature Communications, Journal of Experimental Medicine, Journal of Clinical Investigation and PNAS and additional contributions in Nature, Nature Immunology and the New England Journal of Medicine with more than 26,000 citations and an H-factor of 85. He received several awards including the Carol-Nachmann-Award as the award with the highest international honor in rheumatology research.
Jörg Hans Wilhelm Distler
University Hospital Düsseldorf
Director at the Department of Rheumatology and the Hiller-Research Center at the University Hospital Düsseldorf
Peggy Crow
Weill Cornell Medical College
Mary K. Crow, M.D., is Physician-in-Chief Emeritus at Hospital for Special Surgery, Professor of Medicine at Weill Cornell Medical College, and Professor of Immunology in its Graduate School of Medical Sciences. Dr. Crow is also Senior Scientist, Co-Director of the Mary Kirkland Center for Lupus Research, and Director of the Autoimmunity and Inflammation Program at Hospital for Special Surgery’s Research Institute where she holds the Benjamin M. Rosen Chair in Immunology and Inflammation Research. Dr. Crow received her M.D. from Cornell University Medical College, Internal Medicine and Rheumatology subspecialty training at New York Hospital and Hospital for Special Surgery, and post-doctoral research training at Rockefeller University. The overall goal of Dr. Crow’s research program is to elucidate the underlying mechanisms that account for initiation and amplification of altered immune function and tissue damage in systemic autoimmune diseases, with a particular focus on the prototype systemic autoimmune diseases, systemic lupus erythematosus (SLE) and rheumatoid arthritis. Dr. Crow identified the type I interferon (IFN) pathway as central to the pathogenesis of SLE, and she continues to investigate the cellular and cytokine mediators of immune system activation and inflammation in those disorders. Current interests include the role of endogenous RNA, including genomic retroelements, in IFN pathway activation in systemic autoimmune diseases, along with the role of Toll-like receptor (TLR)-dependent and TLR-independent pathways in innate immune system activation in those disorders. She is also investigating the immune mechanisms that are associated with development of lupus nephritis.
Dr. Crow’s leadership roles have included president of the American College of Rheumatology, president of the Henry Kunkel Society, and chair of the Scientific Advisory Board of the Lupus Research Alliance. In 2017 Dr. Crow was named an honorary member of the European League Against Rheumatism, in 2018 she received the Presidential Gold Medal of the American College of Rheumatology in recognition of outstanding contributions to rheumatology over an entire career, and in 2022 she received the Lee C. Howley Sr. Prize for Arthritis Scientific Research from the Arthritis Foundation.
Weill Cornell Medical College
Physician-in-Chief Emeritus at Hospital for Special Surgery
Professor of Medicine at Weill Cornell Medical College and Professor of Immunology in its Graduate School of Medical Sciences
Senior Scientist, Co-Director of the Mary Kirkland Center for Lupus Research
Director of the Autoimmunity and Inflammation Program at Hospital for Special Surgery’s Research Institute
Board of Directors
Newpath Partners
Dr. Cahill is the Founder and Managing Partner of Newpath Partners, a Boston based life science venture fund focused on building therapeutic companies around transformational scientific discoveries. Prior to Newpath, Dr. Cahill worked at Raptor Group where he helped further establish and lead the life-science and technology investment portfolio. Dr. Cahill received both his M.D. and Ph.D. from Duke University. His graduate work, with Professor Robert Lefkowitz (Nobel Laureate), focused on the biophysical and structural properties of cellular receptors and their signaling. His work has led to numerous peer-reviewed publications and awards. He continues to remain active in basic science research. Newpath is a founding investor in most of their life science companies and focuses on uniquely aligning interests between academic scientists, investors, and management teams. Dr. Cahill is directly involved as either a Director or Observer in the following companies: Myeloid Therapeutics, Prime Medicine, Kisbee Therapeutics, Kojin Therapeutics, Chroma Medicine, Exo Therapeutics, and Seven Sense Biosystems. In addition, Dr. Cahill is involved with non-profit and non-partisan groups such as Scientists to Stop COVID-19 (STSC-19) and the Personal Genetics Education Project (pgEd).
Nagesh Mahanthappa, PhD
Founder, Advisor and Interim CEO of Scholar Rock
Nagesh is a consultant and advisor to biotechnology companies, with a particular focus on start-up and early-stage ventures focused on the discovery and development of novel therapeutics. He was mostly recently the founding employee, President and CEO of Scholar Rock, Inc. During his eight-year tenure at Scholar Rock, Nagesh took the company public and lead two distinct drug candidates into clinical testing.
His previous professional experiences include being the founding employee and VP of Corporate Development at Avila Therapeutics, Inc. (acquired by Celgene in early 2012), and was previously a founding employee of Alnylam Pharmaceuticals where he rose to the position of VP, Scientific & Strategic Development. Prior roles include serving as Manager, Business Development at Vertex Pharmaceuticals, and a series of positions with increasing scientific and commercial responsibility at Ontogeny (now a part of Curis, Inc.). Nagesh started in the biotechnology industry as a Staff Scientist at Cambridge NeuroScience, and was a founder of TwistDx, a DNA diagnostics company acquired by Inverness Medical Innovations (now a part of Abbott Laboratories).
Nagesh completed his post-doctoral training at E.K. Shriver Center for Mental Retardation (then an affiliate of Massachusetts General Hospital) and Harvard Medical School after receiving his Ph.D. in Neurobiology from the California Institute of Technology. Nagesh received his B.A. in Biology and Chemistry from the University of Colorado, and his M.B.A. from the F.W. Olin Graduate School of Management at Babson College.
Executive Chair
Thilo Schroeder, PhD
Nextech Invest
Thilo has been a leading investor in several precision medicine oncology companies and is a board member of Revolution Medicines (RVMD), PMV Pharma (PMVP), Circle Pharma, Atavistik Bio, MOMA Therapeutics and Silverback Therapeutics (SBTX). Past board seats include Blueprint Medicines (BPMC), Peloton Therapeutics (acquired by Merck), Black Diamond Therapeutics (BDTX), IDEAYA Bioscience (IDYA) and ImaginAb.
Thilo began his biotech career at the pioneering cancer immunology company Micromet (acquired by Amgen) while studying at Ecole Supérieure de Biotechnologie de Strasbourg, conducted research at the University of Sydney and obtained his Ph.D. from the University of Zurich, focused on protein engineering in the development of Designed Ankyrin Repeat Proteins (DARPins), a technology now commercialized by Molecular Partners (SWX:MOLN). He also holds a M.Sc. in biotechnology from the Ecole de Supérieure de Biotechnologie de Strasbourg in France, and a B.Sc. in biology from the Technical University of Darmstadt in Germany.
Investors
Targeting exosites represents a breakthrough approach to unlocking traditionally intractable targets through highly selective drugs that reprogram target proteins.
